Regencell Bioscience Holdings Ltd
RGC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RGC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RGC
Regencell Bioscience Holdings Ltd (RGC) is an early-stage Traditional Chinese Medicine (TCM) bioscience company focused on developing standardized liquid-based TCM treatments for neurocognitive disorders such as ADHD and ASD, with no approved products or revenue to date.
Key risk: Going concern uncertainty
Market Cap
$2.72B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2025.
Regencell Bioscience Holdings Ltd (RGC) is an early-stage Traditional Chinese Medicine (TCM) bioscience company focused on developing standardized liquid-based TCM treatments for neurocognitive disorders such as ADHD and ASD, with no approved products or revenue to date.
- Regencell is an early-stage TCM bioscience company with a limited operating history, focusing on research and development of treatments for ADHD, ASD, and infectious diseases [sec · filed 2025-10-31].
- As of June 30, 2025, the company had an accumulated deficit of $25.20 million and reported net losses of $3.58 million for fiscal year 2025 and $4.36 million for fiscal year 2024 [sec · filed 2025-10-31].
- Cash and equivalents stood at $2.4 million as of June 30, 2025, with shareholders' equity of $12.0 million [latest reported financials].
- The company has no saleable products and has not generated any revenue from product sales, funding operations primarily through its initial public offering [sec · filed 2025-10-31].
- Regencell faces substantial doubt about its ability to continue as a going concern, requiring additional financing to meet obligations and fund ongoing development [sec · filed 2025-10-31].
What works
- The company is pursuing a novel approach with a standardized liquid-based TCM formula for ADHD and ASD, which could address unmet needs in neurocognitive disorders [sec · filed 2025-10-31].
- Regencell has ongoing research and development activities aimed at advancing efficacy trials and potentially pursuing additional indications, indicating a structured pipeline [sec · filed 2025-10-31].
What to weigh
- Regencell has incurred operating losses since formation, with net losses of $3.58 million in fiscal 2025 and an accumulated deficit of $25.20 million as of June 30, 2025 [sec · filed 2025-10-31].
- The company has no saleable products or revenue from product sales, and its ability to continue as a going concern is highly contingent on raising additional capital [sec · filed 2025-10-31].
- Cash and equivalents of $2.4 million as of June 30, 2025, are limited relative to ongoing cash burn, with net cash used in operating activities of $3.11 million in fiscal 2025 [sec · filed 2025-10-31].
- The company faces risks related to early-stage development, including uncertainties in successfully completing research studies, obtaining regulatory approvals, and commercializing its TCM treatments [sec · filed 2025-10-31].
From the filings
Quoted directly from source documents.
The company has no saleable products and has not generated any revenue from product sales.
“We have no saleable products and have not generated any revenue from product sales.”
SEC filings · October 31, 2025
Regencell incurred net losses of $3.58 million for fiscal year 2025.
“We incurred total net losses of $3.58 million and $4.36 million, respectively, for the fiscal years ended June 30, 2025 and 2024.”
SEC filings · October 31, 2025
The company's accumulated deficit was $25.20 million as of June 30, 2025.
“As of June 30, 2025, the Company's accumulated deficit amounted to $ 25.20 million.”
SEC filings · October 31, 2025
Substantial doubt exists about the company's ability to continue as a going concern.
“Therefore, uncertainty remains over our ability to meet our liabilities as they fall due”
SEC filings · October 31, 2025
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern within one year; requires additional financing [sec · filed 2025-10-31].
- No revenue or approved products — No saleable products or revenue from product sales; operations funded solely by IPO proceeds [sec · filed 2025-10-31].
- Early-stage development risks — Uncertainty in successfully completing research studies, obtaining regulatory approvals, and commercializing TCM treatments [sec · filed 2025-10-31].
- Limited cash runway — Cash of $2.4M as of June 30, 2025, with net cash used in operations of $3.11M in fiscal 2025 [sec · filed 2025-10-31].
What to watch
- Ability to secure additional financing through public or private markets to fund ongoing operations and development [sec · filed 2025-10-31].
- Progress in efficacy trials for the standardized liquid-based TCM formula for ADHD and ASD [sec · filed 2025-10-31].
- Regulatory developments and potential approvals for TCM treatments in neurocognitive disorders [sec · filed 2025-10-31].
- Cost reduction initiatives and their impact on cash burn rate [sec · filed 2025-10-31].
Sources: SEC filings · Generated August 25, 2026 · How we verify sources →
Run Regencell Bioscience Holdings Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Regencell Bioscience Holdings Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
31
Total value held
$17.9M
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 415,569 | $10.6M |
| susquehanna international group, llp | 72,700 | $1.8M |
| marex group plc | 63,200 | $1.6M |
| citadel advisors llc | 34,300 | $872K |
| jane street group, llc | 28,000 | $712K |
| morgan stanley | 20,078 | $511K |
| bank of america corp /de/ | 17,172 | $437K |
| state street corp | 11,851 | $301K |
| legal & general group plc | 9,903 | $252K |
| lpl financial llc | 8,596 | $219K |
Showing top 10 of 31 institutional holders of Regencell Bioscience Holdings Ltd. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 1.4%
- Days to cover
- 4.8
- Shares short
- 772,547
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RGC short interestFrequently asked questions
What is the AI investment thesis for Regencell Bioscience Holdings Ltd?
Regencell Bioscience Holdings Ltd (RGC) is an early-stage Traditional Chinese Medicine (TCM) bioscience company focused on developing standardized liquid-based TCM treatments for neurocognitive disorders such as ADHD and ASD, with no approved products or revenue to date.
Who is the CEO of Regencell Bioscience Holdings Ltd?
Mr. Yat-Gai Au is the chief executive officer of Regencell Bioscience Holdings Ltd (RGC).
Where is Regencell Bioscience Holdings Ltd headquartered?
Regencell Bioscience Holdings Ltd (RGC) is headquartered in Causeway Bay, Hong Kong.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.